Literature DB >> 7498512

Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.

B E Fischer1, U Schlokat, A Mitterer, M Reiter, W Mundt, P L Turecek, H P Schwarz, F Dorner.   

Abstract

Thorough analysis of multimer composition and molecular structure of recombinant von Willebrand factor (r-vWF) produced by recombinant CHO cells demonstrated r-vWF to be more intact and less proteolytically degraded than plasma-derived vWF (pd-vWF) [B. Fischer et al. (1994) FEBS Lett. 351, 345-348]. In contrast to pd-vWF, r-vWF preparations consisted of pro-vWF (vWF containing covalently attached propeptide) as well as mature vWF subunits forming homo- and hetero-multimers. In order to ensure complete propeptide processing, a r-vWF-producing CHO cell clone was transfected with the cDNA of the human propeptide processing enzyme Furin. A r-vWF/r-Furin co-expressing cell clone was cultivated at industrial scale in high cell density perfusion fermenters. r-vWF obtained from these cells was fully processed. Analysis of r-vWF by multimer analysis revealed a multimer pattern equal in number of high molecular weight multimer to pd-vWF, but absence of satellite bands. Two-dimensional electrophoretic analysis of both the primary dimer and the complete multimer pattern of r-vWF showed that the recombinant coagulation factor was composed exclusively of intact and mature subunits. Since the triplet structure typical to pd-vWF is known to reflect proteolytic degradation, r-vWF thus exhibits an integrity far superior compared to pd-vWF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498512     DOI: 10.1016/0014-5793(95)01218-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Authors:  A Preininger; U Schlokat; G Mohr; M Himmelspach; V Stichler; A Kyd-Rebenburg; B Plaimauer; P L Turecek; H P Schwarz; W Wernhart; B E Fischer; F Dorner
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

2.  Production of recombinant proteins in Chinese hamster ovary cells overexpressing the subtilisin-like proprotein converting enzyme furin.

Authors:  T A Ayoubi; S M Meulemans; A J Roebroek; W J Van de Ven
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

3.  Triplet structure of human von Willebrand factor.

Authors:  B E Fischer; K B Thomas; U Schlokat; F Dorner
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 4.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

5.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

Authors:  Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

Review 6.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.